Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how combining foot-ankle therapeutic exercises with mindful walking affects pain, disability, and quality of life in people with diabetic polyneuropathy. This study aims to improve clinical outcomes and enhance overall well-being by assessing the combined effects of these therapies, addressing gaps in previous research that focused on these treatments separately. Participants will be randomly assigned to one of two groups for 12 weeks. One group will perform foot-ankle exercises including strengthening and flexibility movements alongside mindful walking sessions three times a week, each lasting 30 minutes. The other group will receive standard care combined with mindful walking sessions at the same frequency and duration. Mindful walking involves sensory cues such as kinesthetic, visual, auditory, and tactile inputs. Assessments take place at the start and end of the intervention period. During the study, participants will be evaluated for pain using the Numeric Pain Rating Scale, as well as foot and ankle disability and quality of life. Baseline and 12-week assessments will monitor changes. The study involves regular sessions to track adherence and progress. The total participation duration is 12 weeks, with safety and outcome measures carefully observed throughout the trial.
Actively Recruiting
This trial compares two topical combination treatments for adults aged 18 to 40 with mild-to-moderate acne vulgaris. The study evaluates the effectiveness of 1% nadifloxacin plus 0.025% tretinoin cream against 1% clindamycin plus 0.025% tretinoin cream. The goal is to see which treatment better reduces inflammatory acne lesions after 12 weeks, with focus on newly diagnosed patients without certain other medical conditions. Participants are randomly assigned to apply either nadifloxacin with tretinoin or clindamycin with tretinoin once daily at bedtime to the entire affected facial area after washing and drying the skin. They also use a non-comedogenic moisturizer and sunscreen and avoid other acne treatments. Treatment lasts 12 weeks, with follow-up visits at 4, 8, and 12 weeks to check medication use and side effects. Before treatment and after 12 weeks, a dermatologist unaware of the assigned treatment counts inflammatory, non-inflammatory, and total acne lesions and grades severity using a standardized acne grading system. Side effects like redness, dryness, and itching are monitored at each visit. The main outcome is the reduction in inflammatory lesions at 12 weeks, with secondary measures including overall lesion reduction and acne severity changes.
Actively Recruiting
Researchers are studying the effects of two different aspirin doses, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia. The main goals are to see if the higher dose reduces preeclampsia more effectively and to compare stillbirth rates and newborn birth weights between the two doses. This is a randomized clinical trial involving 224 pregnant women aged 18 to 45 years, who are between 11 and 14 weeks of pregnancy. Participants will be randomly assigned to take either 75 mg or 150 mg of aspirin orally once daily at bedtime, starting from 11 to 14 weeks of pregnancy until 36 weeks. The study uses a parallel design with two groups receiving different aspirin doses. Follow-up visits will occur every two weeks until delivery to monitor progress. During the study, participants will be regularly evaluated for the development of preeclampsia and occurrence of stillbirth. Newborn birth weight will be measured within three hours after birth. The primary outcome is the incidence of preeclampsia from enrollment until delivery. Secondary outcomes include stillbirth rates. Participants will be followed up until delivery, with assessments every two weeks.
Actively Recruiting
Researchers are evaluating two oral medications, metformin and glyburide, to manage blood sugar levels in pregnant women diagnosed with gestational diabetes mellitus GDM who need medication treatment. The study aims to find out whether treatment failure is less common with metformin or glyburide. Treatment failure means that blood sugar levels are not adequately controlled after up to four weeks of treatment. Participants will be randomly assigned to receive either metformin or glyburide. Metformin starts at 850 mg once daily and can be increased up to 2,550 mg per day based on blood sugar levels. Glyburide starts at 2.5 mg twice daily and can be increased up to 20 mg per day. Treatment continues until delivery. Blood sugar is monitored regularly using a glucometer, and if treatment fails or side effects occur, participants may be switched to insulin therapy. During pregnancy and until delivery, participants will have their blood sugar control tracked and maternal outcomes such as preeclampsia, polyhydramnios, and preterm delivery will be recorded. The study also monitors newborn outcomes including birth weight and NICU admission. The main outcome measured is treatment failure within four weeks of starting oral treatment, helping determine which medication better controls blood sugar in this population.
Actively Recruiting
Researchers are evaluating the effects of two corticosteroids, dexamethasone and methylprednisolone, on reducing postoperative pain, swelling, and limited mouth opening trismus in patients with isolated mandibular parasymphysis fractures. This clinical trial addresses the current uncertainty about which steroid is more effective for managing these postoperative complications. The study aims to provide clear evidence to guide clinicians in choosing the best steroid treatment to improve patient recovery after surgery. The trial compares two groups one receiving a single submucosal dose of dexamethasone 8 mg and the other receiving a single submucosal dose of methylprednisolone 40 mg. Both drugs are administered at the surgical site 30 minutes before the incision during open reduction and internal fixation surgery. The study uses a double-blind, randomized design to fairly assess the outcomes of both treatments. Participants will be monitored for facial swelling and pain intensity at baseline, 24 hours, and 72 hours after surgery. Blood samples will be taken to measure serum C-reactive protein, an objective marker of inflammation, at the same time points. Researchers will also track the use of additional pain medication and any side effects. This thorough assessment combining clinical signs and lab tests will help determine which steroid provides better postoperative control of symptoms. The study will continue until late 2026, ensuring comprehensive follow-up.
Actively Recruiting
Researchers are investigating whether Faradic Nerve Stimulation FNS can improve recovery in children with Post-Injection Sciatic Nerve Injury PISNI, a condition caused by nerve damage from improper injections. This injury can lead to pain, muscle weakness, and difficulties moving the legs. The study compares the effects of FNS combined with standard physiotherapy against standard physiotherapy with Transcutaneous Electrical Nerve Stimulation TENS, aiming to find better treatments for nerve recovery in children. Children aged 3 to 19 with PISNI will be randomly divided into two groups one receiving FNS plus standard physiotherapy, and the other receiving TENS plus standard physiotherapy. Both therapies involve electrical stimulation applied through surface electrodes, with sessions lasting 20 to 30 minutes, three times a week, over 8 to 16 weeks. After treatment, participants will be followed for 4 weeks to monitor continued recovery. During the study, children will attend regular therapy sessions and undergo assessments of nerve function using nerve conduction studies, pain levels via pediatric pain scales, functional mobility through disability inventories, and quality of life questionnaires. Follow-up visits will check the lasting effects of treatment. Data will be analyzed to compare improvements in nerve recovery, pain, mobility, and overall well-being between the two groups over the treatment and follow-up periods.
Actively Recruiting
Healthy Volunteer
Support Program Evaluating Psychological Growth and Well-being in Emergency Nurses Exposed to Trauma
Emergency nurses frequently face indirect traumatic experiences through their care for critically ill and injured patients, which can lead to psychological distress and vicarious trauma. Researchers are evaluating the effectiveness of a Vicarious Post-Traumatic Growth VPTG Intervention designed to foster positive psychological changes, resilience, and coping skills among these nurses. This study uses a randomized controlled design to compare the intervention with routine professional support. The intervention includes structured sessions incorporating psychoeducation about trauma, cognitive behavioral therapy techniques, mindfulness exercises, resilience-building activities, stress management training, emotional regulation skills, and peer support. Participants are randomly assigned to either the intervention group receiving this program or a control group continuing standard institutional support. Assessments are conducted at baseline, immediately post-intervention, and at follow-up periods up to six months. Participants will complete questionnaires measuring vicarious post-traumatic growth, vicarious trauma, resilience, coping strategies, psychological well-being, and occupational functioning. These assessments occur at weeks 0, 8, 20, and 32. The study aims to gather evidence to improve psychological support programs for nurses working in high-stress emergency settings, with full participation expected throughout the intervention and follow-up phases over approximately eight months.
Actively Recruiting
Researchers are evaluating whether adding the medicine letrozole to misoprostol can help women have a complete abortion more often compared to using misoprostol alone for treating missed miscarriage, a condition where a pregnancy has stopped developing but has not passed naturally. The study focuses on women up to 13 weeks pregnant with a single pregnancy and excludes those with previous cesarean sections or uterine scars. This phase 4 trial aims to answer if taking letrozole for 3 days before misoprostol increases the chance of complete abortion and if it affects the time for abortion to occur. Participants will be randomly assigned to one of two groups. One group will take letrozole tablets orally once daily for 3 days, followed by a single dose of vaginal misoprostol. The other group will receive placebo tablets for up to 3 days before the vaginal misoprostol dose. The misoprostol dose is 800 micrograms given vaginally. Doctors will monitor the abortion progress closely within 24 hours after the medication to determine if the abortion is complete. During the study, 92 women will be monitored to see if the abortion completes within 24 hours after starting the study medication. If not complete, other medical procedures will be offered as needed. Researchers will examine products of conception to confirm the abortion. This careful monitoring helps understand the effects of adding letrozole to misoprostol for managing missed miscarriage and supports participant safety throughout the trial.
Actively Recruiting
Researchers are comparing two treatments for palmoplantar warts, which are skin growths caused by the human papillomavirus occurring on the palms and soles. The main question is whether carbon dioxide CO2 laser therapy clears warts completely more often than liquid nitrogen cryotherapy after 12 weeks. The study includes adults aged 18 to 50 years with these warts. Participants will be randomly assigned to one of two groups. One group will receive liquid nitrogen cryotherapy using two freeze-thaw cycles once weekly at -196C for up to 8 weeks. The other group will get CO2 laser therapy once weekly for up to 8 weeks. Treatment effectiveness will be checked at 12 weeks. During the study, a dermatologist unaware of the treatments will assess participants for complete wart clearance, partial response, or no response. Researchers will track adverse effects like blistering, ulceration, and infection during treatment. The main outcome measure is treatment efficacy from enrollment through the 12-week final assessment, including 8 weeks of treatment.
Actively Recruiting
Organophosphate poisoning is a serious health issue in regions like Pakistan, where it is common and challenging to manage. This trial evaluates magnesium sulphate as an additional treatment alongside the standard atropine and pralidoxime therapy. The goal is to compare the 15-day mortality rates and the total atropine needed during hospital stays between patients receiving the combined treatment and those receiving standard care alone. The study also aims to understand whether adding magnesium sulphate can better manage complications such as Intermediate Syndrome and reduce the need for ventilators. Participants will be randomly assigned to one of two groups. One group will receive the standard atropine and pralidoxime therapy plus adjunctive magnesium sulphate, which involves an initial loading dose followed by continuous intravenous infusion over 24 hours. The other group will receive only the standard atropine and pralidoxime treatment without magnesium sulphate. This approach allows researchers to assess the potential benefits and impacts of magnesium sulphate as part of the treatment regimen. Throughout the study, participants will be monitored for mortality within 15 days after hospital admission, the occurrence of Intermediate Syndrome within 7 days, and atropine consumption. Researchers will also observe the need for mechanical ventilation, respiratory failure, and length of hospital stay. The study starts with screening and informed consent, followed by treatment and observation during hospitalization. The total participation duration aligns with the critical treatment and monitoring period of up to 15 days post-admission.
1-10 of 13
1